Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer

Clinical Lung Cancer

Volumn 5, Issue 3, 2003, Pages 174-176

  Mott, Frank E ^a,b   Cable, Christian T ^a   Sharma, Neeraj ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

^b Scott White Mem Hosp and Clinics   (United States)

Author keywords

Cisplatin; Nephrotoxicity; Renal toxicity; Thrombocytopenia

Indexed keywords

CARBOPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG RESPONSE; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NEUROPATHY; PHASE 2 CLINICAL TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

EID: 0347600552     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2003.n.030     Document Type: Article

References (15)

1. Marino P, Pampallona S, Preatoni A, et al. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994; 106: 861-865.
2. Schiller J, Harrington D, Belani CP, et al, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
3. Carney DN. Lung cancer - time to move on from chemotherapy. N Engl J Med 2002; 346:126-127.
4. Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 1998; 9:13-21.
5. Mazzanti P, Massacesi C, Rocchi MB, et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2003; 41:81-89.
6. Masotti A, Zannini G, Gentile A, et al. Activity of gemcitabine and carboplatin in advanced non-small cell lung cancer: a phase II trial. Lung Cancer 2002; 36:99-103.
7. Zatloukal P, Petruzelka L.Gemcitabine/Carboplatin in advanced non-small cell lung cancer. Lung Cancer 2002; 38(suppl 2):S33-S36.
8. Domine M, Casado V, Estevez LG, et al. Gemcitabine and carboplatin for patients With advanced non-small cell lung cancer. Semin Oncol 2001; 28:4-9.
9. Iaffaioli RV, Tortoriello A, Facchini G, et al. Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. J Clin Oncol 1999; 17:921-926.
10. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
11. National Cancer Institute, Cancer Therapy Evaluation Program. Common Criteria Toxicity Manual, version 2.0. Available at: http://ctep.cancer.gov. Accessed June 1, 1999.
12. Mott FE, Sharma N, Ashley P. Malignant pleural effusion in non-small cell lung cancer - time for a stage revision? Chest 2001; 119:317-318.
13. Giaccone G, Johnson DH, Manegold C, et al. A phase III clinical trial of ZD1839 ("Iressa") in combination with gemcitabine and cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer (INTACT 1). Ann Oncol 2002; 13(suppl 5):2 (Abstract #4O).
14. Johnson DH, Herbst R, Giaccone G, et al. ZD1839 ("Iressa") in combination with paclitaxel and carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC): Initial results from a phase III trial (INTACT 2). Ann Oncol 2002; 13(suppl 5):127 (Abstract #468O).
15. Socinski M, Baggstrom M, Hensing T. Duration of therapy in advanced, metastatic non-small lung cancer. Clin Adv Hematol Oncol 2003; 1:33-38.